Exagen

Seronegative rheumatoid arthritis can present a diagnostic challenge. When RF and anti-CCP are negative, RA may still remain in the differential, particularly when clinical findings suggest inflammatory arthritis.

A broader diagnostic evaluation may help support clinical decision-making, including assessment of:

🔗 Synovitis and joint involvement pattern
🔗 Symptom duration and extra-articular manifestations
🔗 Inflammatory markers and imaging findings
🔗 Additional serum biomarkers such as anti-RA33 and anti-PAD4
🔗 Ongoing reassessment as the clinical picture evolves

Seronegativity does not exclude RA. Integrating clinical, serologic, imaging, and longitudinal data can help provide a more complete diagnostic picture.

🔍 For clinicians: when conventional RA markers are negative, what factors do you find most helpful in deciding whether to continue evaluating for RA?

Follow us to learn how biomarkers can support the evaluation of suspected RA.

Anti-CCP may provide clinically relevant insight early in the rheumatoid arthritis evaluation process.

Anti-CCP antibodies can be present before clinically apparent RA and are considered more specific for RA than rheumatoid factor, making them a useful marker when evaluating patients with suspected inflammatory arthritis. Results should be interpreted alongside symptoms, physical exam, imaging, and other laboratory findings.

For clinicians, early biomarker insight may help support a more informed evaluation pathway and treatment planning when RA is suspected.

🔍️ How are you incorporating anti-CCP into the workup for patients with early or ambiguous inflammatory arthritis?

Myositis specific antibodies can provide important information for diagnosing and characterizing idiopathic inflammatory myopathies (IIM), but consistency across testing platforms remains an important consideration in research and clinical trial settings.

𝗜𝗻 𝗮 𝗰𝗼𝗺𝗽𝗮𝗿𝗮𝘁𝗶𝘃𝗲 𝘀𝘁𝘂𝗱𝘆 𝗼𝗳 𝗶𝗺𝗺𝘂𝗻𝗼𝗮𝘀𝘀𝗮𝘆 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀, 𝗘𝘅𝗮𝗴𝗲𝗻 𝗲𝘃𝗮𝗹𝘂𝗮𝘁𝗲𝗱 𝗺𝘆𝗼𝘀𝗶𝘁𝗶𝘀-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 𝗮𝗰𝗿𝗼𝘀𝘀 𝗣𝗮𝗿𝘁𝗶𝗰𝗹𝗲-𝗕𝗮𝘀𝗲𝗱 𝗠𝘂𝗹𝘁𝗶-𝗔𝗻𝗮𝗹𝘆𝘁𝗲 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 (𝗣𝗠𝗔𝗧), 𝗘𝗻𝘇𝘆𝗺𝗲-𝗟𝗶𝗻𝗸𝗲𝗱 𝗜𝗺𝗺𝘂𝗻𝗼𝘀𝗼𝗿𝗯𝗲𝗻𝘁 𝗔𝘀𝘀𝗮𝘆 (𝗘𝗟𝗜𝗦𝗔), 𝗮𝗻𝗱 𝗟𝗶𝗻𝗲 𝗜𝗺𝗺𝘂𝗻𝗼𝗮𝘀𝘀𝗮𝘆 (𝗟𝗜𝗔) 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺𝘀, 𝘄𝗶𝘁𝗵 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗰𝗿𝗼𝘀𝘀-𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗮𝘀𝘀𝗮𝘆 𝗹𝗶𝗻𝗲𝗮𝗿𝗶𝘁𝘆.

Key takeaways include:

👉 PMAT and ELISA showed strong agreement for select antibodies, including anti-Mi-2, anti-MDA5, and anti-TIF1-γ.
👉 Tri-method comparison data across PMAT, ELISA, and LIA provided additional insight into platform consistency.
👉 Linearity findings varied by analyte and platform, supporting future research into whether quantitative MSA assessment may help evaluate antibody-targeted therapies.

For biopharma and clinical trial teams, these findings may be relevant when patient characterization, site-to-site consistency, and future quantitative biomarker strategies are important considerations.

At Exagen, our specialized autoimmune biomarker expertise and centralized laboratory model help support complex clinical research programs in autoimmune disease.